Isolation, identification and structural characterization of forced degradation products of mobocertinib using LC-MS/MS and NMR by Shweta Mishra, Ashlesha Chauhan, R. Ramajayam

Subjects: “…Mobocertinib…”
Get full text

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions by Mohd Imran, Shah Alam Khan, Mohammed Kanan Alshammari, Meshal Ayedh Alreshidi, Abeer Abdullah Alreshidi, Rawan Sulaiman Alghonaim, Fayez Aboud Alanazi, Sultan Alshehri, Mohammed M. Ghoneim, Faiyaz Shakeel

Subjects: “…mobocertinib…”
Get full text

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations by Zhang SS, Zhu VW

Subjects: “…mobocertinib…”
Get full text

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors by Ikei S. Kobayashi, MD, PhD, William Shaffer, MS, Hollis Viray, MD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Subjects: Get full text

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations by Pedro E.N.S. Vasconcelos, MS, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Subjects: Get full text

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer by Waleed Kian, Petros Christopoulos, Areen A. Remilah, Esther Levison, Elizabeth Dudnik, Walid Shalata, Bilal Krayim, Ranin Marei, Alexander Yakobson, Martin Faehling, Dolev Kahala, Inbal Sara Granot, Dina Levitas, Nir Peled, Laila C. Roisman

Subjects: “…mobocertinib…”
Get full text

Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab by Elena Corral de la Fuente, María Eugenia Olmedo García, Inmaculada Orejana Martín, Amparo Benito Berlinches, Ana Gómez Rueda, Yolanda Lage Alfranca, Pilar Garrido

Subjects: Get full text

The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions by Kaakour D, Nagasaka M

Subjects: Get full text

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report by Josette Kamel, BA, Natalie Meeder, BA, Sandra Cuellar, PharmD, BCOP, David Chan, PharmD, PhD, Michael Huber, MD, MS, Mary Pasquinelli, DNP, Alicia Hulbert, MD, Karam Khaddour, MD, Lawrence Feldman, MD

Subjects: Get full text

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors by Pedro E.N.S. Vasconcelos, MS, Carol Gergis, MS, Hollis Viray, MD, Andreas Varkaris, MD, PhD, Masanori Fujii, MD, PhD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Subjects: Get full text

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease by Giulio Metro, Andrea De Giglio, Biagio Ricciuti, Marco Siringo, Daniele Marinelli, Alain Gelibter, Federica Pecci, Rossana Berardi, Luca Cantini, Alessandro Di Federico, Elisa Andrini, Mirta Mosca, Giuseppe Lamberti, Marta Brambilla, Giannis Mountzios

Subjects: Get full text